CD274 and non-small cell lung carcinoma: In fact, many randomized clinical trials have suggested that combining an anti-PD-1 mAb (pembrolizumab, camrelizumab, tislelizumab, sintilimab) or anti-PD-L1 inhibitor (atezolizumab) with platinum-doublet chemotherapy could significantly improve PFS or OS compared with chemotherapy alone in both squamous and nonsquamous advanced NSCLC, irrespective of the level of PD-L1 expression [16,18,19,23,32,34,41].